Generex
Biotechnology (Nasdaq: GNBT)
After
10 years of development Oral-lyn has been found to be as effective as injected
insulin for treatment of diabetes and is ready for commercialization.
Website:
www.generex.com
For the Complete Profile please
visit www.smallcapreview.com/gnbt.htm
GNBT
Investor Highlights:
-
GNBT
has developed Oral-lyn(TM), an oral insulin spray for the treatment of
diabetes that replaces insulin injections.
-
After
10 years of development Oral-lyn has been found to be as effective as
injected insulin and is ready for commercialization.
-
Sales
could start as early as the first half of 2005 in South America. Canada and
Europe is the next target market with the U.S. to follow.
-
GNBT's
delivery system known as RapidMist(TM), has the potential to replace
injected drugs, including Morphine, Fentanyl, Heparin and flu vaccines.
-
The
market for
injectable drugs in a non-injectable form is estimated to be $15 billion.
-
Proven Drug
Delivery Technology Platform: RapidMistTM allows for the buccal delivery of
large molecule drugs.
-
ORAL-LYN is
currently in Phase IIB of ongoing clinical studies and has shown similar
results as compared to injection.
-
Antigen
Express, Inc. ??“ Generex subsidiary, focused on the development of
immunomedicines. Received grants totaling $1.85 million.
-
GNBT has 18
patents and 60 patent applications.
-
Recently
had its first publication demonstrating that Oral-lyn is able to replace
subcutaneous insulin in treating patients with type 1 diabetes.
-
Announced
that University Campus Bio-Medico and other centres in Europe are poised to
commence Phase III studies aimed at demonstrating that Oral-lyn can achieve
optimal metabolic control evaluated via glycosylated hemoglobin, a
well-known parameter for determining optimization of glucose metabolism.
Profile
Generex
Biotechnology (Nasdaq: GNBT)
is engaged in the research and development of drug delivery systems and
technologies. Generex has developed a proprietary platform technology for the
delivery of drugs into the human body through the oral cavity (with no deposit
in the lungs). The Company's proprietary liquid formulations allow drugs
typically administered by injection to be absorbed into the body by the lining
of the inner mouth using the Company's proprietary RapidMist(TM) device.
The potential
benefits are compelling. Pain-free, needle-free, noninvasive drug delivery.
Dosages administered accurately and conveniently. Improved quality of life for
people who currently depend on regular, painful injections to maintain their
health.
The Company's flagship product, oral
insulin (Oral-lyn(TM)), is in late stage clinical trials around the world.
In August 2003, Generex acquired
Antigen Express, Inc. Antigen Express is a platform and product-based company
developing proprietary vaccine formulations for large, unmet medical needs. The
focus is on stimulating critical members of the immune response, known as T
helper cells.
Overview
Generex Biotechnology has a
market ready solution to a central challenge in diabetes treatment ??“ ending
the pain and hassle of insulin injections. Ever since scientists early in the
20th century learned that diabetes was caused by the body??™s inability to
produce a normal supply of insulin, patients have had to administer insulin by
injection. Alternatives that have been developed in recent years ??“ pumps or
needle-less ???pens??? ??“ are still invasive and/or expensive. Pharmaceutical
companies have tried to develop a truly non-invasive insulin product that is
pain-free, easy to use and free from serious side effects.
Among today??™s competing
technologies, only Oral-lyn, an insulin spray for treatment of diabetes, meets
all those tests. After 10 years of development, Oral-lyn is ready for market and
could produce enormous revenue growth for the company. Generex is little known
outside a small community of investors focused on drug delivery and diabetes
treatment. In the next few months, however, the expected commercial entry of
Oral-lyn in
South America
could raise Generex??™s profile sharply, and may see a commensurate rise in
their share price. Small companies in drug and medical-device development are,
of course, inherently high-risk investments. But aggressive investors who take
an early stake in these firms can profit several times over. Generex has the
profile of being one such potential winner.
Recent News and Press
Releases
Generex
Biotechnology Collaborator Reports an Advance in Intra-Tumor Gene Therapy for
Cancer
Generex
Biotechnology & University Campus Bio-Medico Announce Publication Of Oral
Insulin Research Study
For the Complete Profile please visit www.smallcapreview.com/gnbt.htm
Disclaimer
SmallCapReview.com feature stock reports are
intended to be stock ideas, NOT recommendations. Please do your own research
before investing. It is crucial that you at least look at current SEC filings
and read the latest press releases. For continuing coverage of GNBT, please
sign up for our free newsletter. Information contained in this report was
extracted from current documents filed with the SEC, the company web site and
other publicly available sources deemed reliable. For more information see our
disclaimer section, a link of which can be found on our web site. This document
contains forward-looking statements, particularly as related to the business
plans of the Company, within the meaning of Section 27A of the Securities Act of
1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to
the safe harbor created by these sections. Actual results may differ materially
from the Company's expectations and estimates. The information provided herein
is not intended for distribution to, or use by, any person or entity in any
jurisdiction or country where such distribution or use would be contrary to law
or regulation or which would subject us to any registration requirement within
such jurisdiction or country.
Copyright
SmallCapReview.com. All rights reserved. SmallCapReview.com is not a Registered
Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All
materials presented on our web site and individual reports released to the
public through this web site, e-mail or any other means of transmission are not
to be regarded as investment advice and are only for informative purposes.
Before making a purchase or sale of any securities featured on our web site
or mentioned in our reports, we strongly encourage and recommend consultation
with a registered securities representative. This is not to be construed as
a solicitation or recommendation to buy or sell securities. As with any stock,
companies we select to profile involve a degree of investment risk and
volatility. Particularly Small-Caps and OTC-BB stocks. All investors are
cautioned that they may lose all or a portion of their investment if they decide
to make a purchase in any of our profiled companies. Past performance of our
profiled stocks is not indicative of future results. The accuracy or
completeness of the information on our web site or within our reports is only as
reliable as the sources they were obtained from. The profile and opinions
expressed herein are expressed as of the date the profile is posted on site and
are subject to change without notice. No investor should assume that reliance on
the views, opinions or recommendations contained herein will produce profitable
results. SmallCapReview.com may hold positions in securities mentioned herein,
and may make purchases or sales in such securities featured on our web site or
within our reports. In order to be in full compliance with the Securities Act
of 1933, Section 17(b), SmallCapReview.com will disclose in it's
disclaimer, what, if any compensation was received for our efforts in
researching, presenting and disseminating this information to our subscriber
database and featuring the report on the SmallCapReview.com web site.
SmallCapReview.com has been compensated three thousand dollars by a third party
for its efforts in presenting the Generex Biotechnology profile on its web site
and distributing it to its database of subscribers. SmallCapReview.com may
decide to purchase or sell shares on a voluntary basis in the open market
before, during or after the profiling period of this report. Information
presented on our web site and within our reports contain "forward looking
statements" within the meaning of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. Any statements that
express or involve discussions with respect to predictions, expectations,
beliefs, plans, projections, objectives, goals, assumptions or future
events or performance are not statements of historical fact and may be "forward
looking statements." Forward looking statements are based on expectations,
estimates and projections at the time the statements are made that involve a
number of risks and uncertainties which could cause actual results or events to
differ materially from those presently anticipated. Forward looking statements
in this action may be identified through the use of words such as
???expects??™???, ???will,??? ???anticipates,??? ???estimates, ???believes,???
or that by statements indicating certain actions ???may,??? ???could,??? or
???might??? occur.
THE READER
SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN
ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND
CARRIES A HIGH DEGREE OF RISK.
We
encourage our readers to invest carefully and read the investor information
available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov
and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com
. Readers can review all public filings by companies at the SEC's EDGAR
page. The NASD has published information on how to invest carefully at its web
site.
|
